Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
EPRX
Stock Latest News
Company Announcements
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K
2d ago
6K
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders
2d ago
6K
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference
3d ago
6K
EPRX
Premium
The Fly
Eupraxia Pharmaceuticals initiated with a Buy at Stifel
11d ago
EPRX
Premium
Ratings
Analyst Reiterates Buy on EP-104GI Potential and Cash Runway, Maintains $16 Price Target
16d ago
EPRX
Premium
Ratings
Eupraxia: Encouraging EP-104GI Data and Strong Cash Runway Support Buy Rating, Price Target Reiterated at $11
17d ago
EPRX
Premium
Ratings
Robust EP-104GI Data and Strengthened Balance Sheet Underpin Buy Rating on Eupraxia Ahead of Phase IIb RESOLVE Study
17d ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing
19d ago
6K
EPRX
Premium
The Fly
Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year
19d ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI
25d ago
6K
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW
26d ago
6K
EPRX
Premium
Ratings
Buy Rating Backed by Favorable Safety and Promising Efficacy Data for EP-104GI in Eosinophilic Esophagitis
27d ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline
30d ago
6K
EPRX
Premium
The Fly
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer
30d ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026
1M ago
6K
EPRX
Premium
Ratings
Eupraxia Pharmaceuticals: Strong EP-104GI Clinical Durability and Dose-Response Support Buy Rating and Favorable Risk-Reward
1M ago
EPRX
Premium
Company Announcements
Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial
1M ago
6K
EPRX
Premium
Ratings
Encouraging EP-104GI EoE Data and Strong Cash Runway Underpin Buy Rating on Eupraxia
1M ago
EPRX
Premium
Ratings
Compelling EP‑104GI Eosinophilic Esophagitis Data and Safety Profile Underpin Buy Rating and Attractive Risk‑Reward Ahead of Phase IIb Catalysts
1M ago
EPRX
Premium
The Fly
Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial
1M ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences
2M ago
EPRX
Premium
Ratings
Eupraxia Pharmaceuticals: Underdiagnosed EoE Market Expands Upside, Supporting Buy Rating on EPRX
2M ago
EPRX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
